The rationale for targeting the LOX family in cancer.
The therapeutic targeting of extracellular proteins is becoming hugely attractive in light of evidence implicating the tumour microenvironment as pivotal in all aspects of tumour initiation and progression. Members of the lysyl oxidase (LOX) family of proteins are secreted by tumours and are the subject of much effort to understand their roles in cancer. In this Review we discuss the roles of members of this family in the remodelling of the tumour microenvironment and their paradoxical roles in tumorigenesis and metastasis. We also discuss how targeting this family of proteins might lead to a new avenue of cancer therapeutics.
Hypoxia & Metastasis Team, The Institute of Cancer Research, London SW3 6JB, UK.
Holly E
HE
Barker
Thomas R
TR
Cox
Janine T
JT
Erler
D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000201:enzymology* / Q000473:pathology / Q000628:therapy*; D008249:Protein-Lysine 6-Oxidase / Q000378:metabolism*; D059016:Tumor Microenvironment
D008249:Protein-Lysine 6-Oxidase